Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie för att utvärdera behandlingsmönster och behandlingsföljsamhet hos deltagare med tidig HER2-positiv bröstcancer efter decentralisering av behandlingen (Close2HER)

5 november 2026 uppdaterad av: Hoffmann-La Roche

Real-World-studie av behandlingsmönster och behandlingsföljsamhet vid tidig HER2-positiv bröstcancer i Serbien efter decentralisering av behandling (Close2HER)

The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).

This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.

Studieöversikt

Status

Rekrytering

Studietyp

Observationell

Inskrivning (Beräknad)

100

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Studera Kontakt Backup

  • Namn: Reference Study ID Number: ML46477 https://forpatients.roche.com/ No attachments to email below.
  • Telefonnummer: 888-662-6728 (U.S. Only)
  • E-post: global-roche-genentech-trials@gene.com

Studieorter

    • Bolnička 65
      • Loznica, Bolnička 65, Serbien, 15300
        • Rekrytering
        • Health Centre Loznica
    • Bratstva Jedinstva 135
      • Požarevac, Bratstva Jedinstva 135, Serbien, 12000
        • Rekrytering
        • General Hospital Požarevac
    • Dragiše Mišovića 1
      • Bor, Dragiše Mišovića 1, Serbien, 19210
        • Rekrytering
        • Healthcare Centre Bor
    • Dunavska 1-3
      • Kladovo, Dunavska 1-3, Serbien, 19320
        • Rekrytering
        • Health Centre Kladovo
    • Knez Mihailova 51
      • Smederevo, Knez Mihailova 51, Serbien, 11300
        • Rekrytering
        • Health Centre ''Sveti Luka'' Smederevo
    • Miloša Trebinjca 11
      • Pančevo, Miloša Trebinjca 11, Serbien, 26000
        • Rekrytering
        • General Hospital Pančevo
    • Pasterova 14
      • Belgrade, Pasterova 14, Serbien, 11000
        • Rekrytering
        • Institute for Onocology and Radiology of Serbia
    • Popa Karana 2-4
      • Šabac, Popa Karana 2-4, Serbien, 15000
        • Rekrytering
        • General Hospital "Dr Laza K. Lazarevic" Sabac
    • Sinđelićeva 62
      • Valjevo, Sinđelićeva 62, Serbien, 14000
        • Rekrytering
        • Health Centre Valjevo
    • Vuka Karadžića 147
      • Smederevska Palanka, Vuka Karadžića 147, Serbien, 11420
        • Rekrytering
        • General Hospital ''Stefan Visoki'' Smederevska Palanka

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study population will consist of participants diagnosed with HER2-positive eBC who are initiating or undergoing treatment following a nationwide healthcare policy change in Serbia that decentralized the administration of anti-HER2 therapies.

Beskrivning

Inclusion Criteria:

  • Diagnosis of stage II and III HER2+ eBC according to European Society For Medical Oncology (ESMO) guidelines
  • Underwent curative-intent surgical resection for BC
  • Histologically documented HER2-positive BC (determined per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] guidelines) before or after surgery

Exclusion Criteria:

  • Any medical or psychiatric condition that, in the investigator's opinion, would compromise the participant's ability to provide informed consent or to complete study-related questionnaires
  • Receipt of prior neoadjuvant or adjuvant therapy for HER2+ BC at a center other than the 10 participating study sites (Bor, Kladovo, Institute for oncology and Radiology of Serbia (IORS), Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, Valjevo)
  • Participants administratively belonging to the following secondary centers: Bor, Kladovo, Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, or Valjevo, who initiated neoadjuvant therapy at IORS instead of their local secondary center

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Group 1: Cohort A

Participants who received neoadjuvant therapy and achieved pathological complete response (pCR) and receive their adjuvant treatment at a designated secondary or tertiary center, administratively assigned based on their place of residence will be observed to assess the impact on quality of life (QoL) and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

Group 2: Cohort B

Participants who received neoadjuvant therapy at a secondary center and were subsequently found to have residual invasive disease will be referred to a centralized referent tertiary institution to receive their adjuvant treatment and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

Group 1: Cohort C

Participants who received neoadjuvant therapy at their designated tertiary center, which is the institution administratively assigned based on their place of residence, and subsequently found to have residual invasive disease will continue with adjuvant treatment at the same institution, and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

Group 1: Cohort D

Participants who missed neoadjuvant therapy and underwent primary BC surgery will start adjuvant treatment at their designated secondary hospital or tertiary center, which is the institution administratively assigned based on their place of residence and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Behandlingsföljsamhetsgrad
Tidsram: Upp till 2,25 år
Upp till 2,25 år

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Behandlingsfärdigställande grad för anti-HER2-behandling
Tidsram: Upp till 2,25 år
Upp till 2,25 år
Procentandel deltagare med ≥1 dosfördröjningar som överskrider ett fördefinierat tröskelvärde (3 veckor) från det schemalagda datumet
Tidsram: Upp till 2,25 år
Upp till 2,25 år
Tid till inledning av adjuvant behandling
Tidsram: Tid från operation till start av adjuvant behandling (upp till cirka 1,25 år)
Tid från operation till start av adjuvant behandling (upp till cirka 1,25 år)
Mean Travel Burden Between Group 1 (Cohorts A, C, D) and Group 2 (Cohort B) During the Adjuvant Therapy Phase
Tidsram: Up to 2.25 years

Travel Burden is a composite measure encompassing both objective and subjective components. Objective travel burden is defined by the one-way travel distance (in kilometers [km]) and one-way travel time (in minutes) from the participant's residence to the treatment center. Subjective travel burden will capture the participant's personal experience and will be assessed using patient-reported outcomes collected via dedicated questionnaires.

Up to 2.25 years
Cohort B: Change in Intra-participant Travel Burden Between the Neoadjuvant and Adjuvant Treatment Centers
Tidsram: Up to 2.25 years

Travel Burden is a composite measure encompassing both objective and subjective metrices. Objective travel metrics include driving distance and travel time and subjective, patient-reported metrics include out-of-pocket costs, mode of transport, and perceived travel-related challenges. Intra-participant travel burden between the Neoadjuvant and Adjuvant treatment centers will be done as a longitudinal analysis of the change in these metrics from the neoadjuvant to the adjuvant phase.

Up to 2.25 years
Difference in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/QoL Score, Between Participants of Cohort B and Cohort C
Tidsram: At 6 months post-baseline

EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better health-related quality of life (HRQoL).

At 6 months post-baseline
Mean Intra-patient Change in the EORTC QLQ-C30 GHS/QoL Score
Tidsram: Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12

EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better HRQoL.

Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
Time to Neoadjuvant Treatment Initiation
Tidsram: At Baseline

Time to Neoadjuvant Treatment Initiation was defined as time from early breast cancer (eBC) diagnosis to the start of neoadjuvant treatment. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

At Baseline
Time to Surgery
Tidsram: At Baseline

Time to surgery was defined as the time from the neoadjuvant treatment completion to surgery. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

At Baseline
Percentage of Participants Treated at Least Once With Neoadjuvant Therapy
Tidsram: At Baseline

Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

At Baseline
Percentage of Participants Not Treated With Neoadjuvant Therapy
Tidsram: At Baseline

Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

At Baseline
Percentage of Participants With pCR After Neoadjuvant Systemic Therapy Completion
Tidsram: At Baseline

Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

At Baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Clinical Trials, Hoffmann-La Roche

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 februari 2026

Primärt slutförande (Beräknad)

31 oktober 2028

Avslutad studie (Beräknad)

31 oktober 2028

Studieregistreringsdatum

Först inskickad

7 april 2026

Först inskickad som uppfyllde QC-kriterierna

7 april 2026

Första postat (Faktisk)

14 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera